Ahead of the UN General Assembly High-Level Meeting on TB, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

The Indian Patent Office takes a laudable step that will pave the way for generic manufacturing of a key TB drug.

Treatment Action Group and the 1/4/6x24 Campaign Coalition launch the 1/4/6x24 World TB Day Toolkit to support advocacy the week of World TB Day for access to shorter, safer regimens for TB prevention and treatment.

A few recent Campaign updates from Treatment Action Group and allies.
Contact david.branigan@treatmentactiongroup.org for more information on how to be part of the 1/4/6x24 Campaign.

Materials designed to equip civil society and community-based organizations with the information they need to advocate for equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6×24 Campaign.

Several key global health actors have already set plans into motion to answer the 1/4/6x24 Campaign call to action, making major commitments. Two countries have also stepped up as global leaders.

On 28 October 2022, the 1/4/6x24 Campaign Coalition hosted a session at the USAID TB Symposium '1/4/6x24 Campaign Call to Action: Kick Starting Momentum Toward the United Nations High-Level Meeting.' Full details about the event are available here.

On 28 October 2022, the 1/4/6x24 Campaign Coalition will host a session at the USAID TB Symposium '1/4/6x24 Campaign Call to Action: Kick Starting Momentum Toward the HLM.'